Published in Expert Opin Biol Ther on May 26, 2011
Rapid single-colony whole-genome sequencing of bacterial pathogens. J Antimicrob Chemother (2013) 1.66
Multivalent glycoconjugates as anti-pathogenic agents. Chem Soc Rev (2012) 1.41
Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc Natl Acad Sci U S A (2013) 1.16
Bacterial outer membrane vesicles and vaccine applications. Front Immunol (2014) 1.16
Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother (2013) 1.10
Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol (2012) 1.06
An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS One (2013) 0.96
Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates. Infect Immun (2013) 0.95
Routine vaccination against MenB: considerations for implementation. Hum Vaccin Immunother (2013) 0.87
The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential. MBio (2013) 0.86
Phase variation of PorA, a major outer membrane protein, mediates escape of bactericidal antibodies by Neisseria meningitidis. Infect Immun (2013) 0.86
Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii. Sci Rep (2016) 0.83
Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis. PLoS One (2013) 0.83
Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA), one of the main antigens of a novel vaccine against Neisseria meningitidis. J Biol Chem (2011) 0.83
The distribution and 'in vivo' phase variation status of haemoglobin receptors in invasive meningococcal serogroup B disease: genotypic and phenotypic analysis. PLoS One (2013) 0.80
Potential Roles of Fungal Extracellular Vesicles during Infection. mSphere (2016) 0.76
Meningococcal group B vaccines. Hum Vaccin Immunother (2013) 0.76
Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned? Hum Vaccin Immunother (2016) 0.75
Genotypic analysis of meningococcal factor h-binding protein from non-culture clinical specimens. PLoS One (2014) 0.75
Frequent capsule switching in 'ultra-virulent' meningococci - are we ready for a serogroup B ST-11 complex outbreak? J Infect (2017) 0.75
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 2.91
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med (2011) 2.72
Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis (2007) 2.45
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol (2010) 2.11
Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med (2010) 1.99
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine (2007) 1.85
Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine (2009) 1.79
Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods (2004) 1.74
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis (2006) 1.66
Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis (2013) 1.66
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine (2003) 1.60
Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol (2004) 1.59
Added value of PCR-testing for confirmation of invasive meningococcal disease in England. J Infect (2013) 1.58
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (2006) 1.57
Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine (2012) 1.54
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis (2006) 1.52
Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol (2005) 1.51
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine (2013) 1.49
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine (2009) 1.44
A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis (2008) 1.44
Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination. Pediatr Infect Dis J (2015) 1.38
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol (2010) 1.36
Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines (2011) 1.35
Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis (2002) 1.33
Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol (2009) 1.32
Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis (2007) 1.30
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30
Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol (2009) 1.30
A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med (2008) 1.30
Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis (2012) 1.26
Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J (2005) 1.24
Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis (2007) 1.23
Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol (2004) 1.22
Genetics of capsule O-acetylation in serogroup C, W-135 and Y meningococci. Mol Microbiol (2004) 1.19
Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol (2008) 1.19
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine (2012) 1.19
Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol (2011) 1.18
Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS One (2011) 1.16
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun (2006) 1.15
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis (2013) 1.13
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog (2012) 1.10
Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol (2008) 1.10
Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol (2010) 1.09
Neisseria lactamica protects against experimental meningococcal infection. Infect Immun (2002) 1.09
Meningococcal disease and prevention at the Hajj. Travel Med Infect Dis (2009) 1.08
Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis (2011) 1.07
Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol (2012) 1.06
Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. Clin Vaccine Immunol (2009) 1.06
Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine (2003) 1.05
Immunity to tetanus and diphtheria in the UK in 2009. Vaccine (2012) 1.05
Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008. PLoS One (2013) 1.04
Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis. Clin Infect Dis (2011) 1.04
Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol (2006) 1.02
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine (2006) 1.02
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis (2016) 1.00
Sequence conservation of pilus subunits in Neisseria meningitidis. Vaccine (2010) 0.98
Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines (2004) 0.98
Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine. Clin Vaccine Immunol (2006) 0.97
Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol (2007) 0.97
Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol (2007) 0.97
Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol (2004) 0.97
Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis. J Immunol (2003) 0.96
Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin Diagn Lab Immunol (2004) 0.96
Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin (2007) 0.95
Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol (2012) 0.95
Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide. Clin Diagn Lab Immunol (2005) 0.94
Evolving meningococcal immunization strategies. Expert Rev Vaccines (2014) 0.94
Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin Vaccine Immunol (2009) 0.93
Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine (2002) 0.93
Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child (2013) 0.93
Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines (2010) 0.92